Summary: First-in-Human Study of Novel Coronary Laser IVL System (Sola) by FastWave Medical.<\/p>\n
Source: Sola\u2122 Coronary Laser IVL Feasibility Study, \u2013 IRB Approved 2025<\/p>\n
1. Technology Overview:
\nFastWave Medical has initiated clinical evaluation of a new laser-based intravascular lithotripsy (IVL) system, named Sola\u2122, designed to modify calcified coronary artery lesions more safely and effectively.
\n2. Device Design:
\n\u2022 Sola\u2122 is a rupture-resistant balloon catheter that emits 360\u00b0 pressure pulses using laser energy.
\n\u2022 Developed to improve on existing IVL technologies by enhancing crossability, energy precision, and ease of use\u2014eliminating extra procedural steps.
\n3. Study Details:
\n\u2022 A first-in-human, multicenter feasibility study was launched under Institutional Review Board (IRB) approval on May 7, 2025.
\n\u2022 The study evaluates safety, lesion crossing success, and initial performance outcomes in patients with moderate to severe coronary artery calcification.
\n4. Early Clinical Results:
\n\u2022 100% procedural success in crossing target lesions.
\n\u2022 No major adverse events reported within 30 days.
\n\u2022 Device showed exceptional deliverability, particularly in complex and tortuous anatomy.
\n\u2022 Operates at a 5 Hz pulse frequency, reducing ischemic time\u2014especially valuable in patients with reduced cardiac output.
\n5. Clinical Relevance:
\n\u2022 Laser IVL represents a less traumatic alternative to high-pressure balloon angioplasty or rotational atherectomy.
\n\u2022 Offers improved lesion preparation for stent delivery in heavily calcified arteries.
\n6. Next Steps:
\n\u2022 The data will be used to support regulatory submissions and guide the design of a pivotal U.S. clinical trial for FDA clearance.
\n\u2022 FastWave enters the competitive IVL market alongside established technologies such as Shockwave.<\/p>\n
Scientific Reference:
\nSola\u2122 Coronary Laser IVL Feasibility Study
\n\u2022 IRB Approval: May 7, 2025
\n\u2022 Study Design: Multicenter, first-in-human safety and performance study
\n\u2022 Clinical Milestone: 100% lesion crossing success, no 30-day MACE
\n\u2022 Planned Next Phase: U.S. pivotal trial for regulatory approval<\/p>\n